Description

(Aminooxy)acetamide-Val-Cit-PAB-MMAE (MMAE 5) is an intermediate used in the synthetic preparation of drug-linker conjugates for ADC. (Aminooxy)acetamide-Val-Cit-PAB-MMAE is conjugated to polyamide via oxime bond formation to form MMAE polyamide conjugate. Then MMAE polyamide conjugate can be conjugated to Trastuzumab, to make ADC[1].–20°C (Powder, sealed storage, away from moisture and light)-Applications–Formula-C60H97N11O14-Citation–References-[1]Ouberai Myriam, et al. Preparation of antibody-drug conjugates using polymers and crosslinkers. World Intellectual Property Organization, WO2020128488 A1. 2020-06-25. -CASNumber-2446645-88-9-MolecularWeight-1196.48-Compound Purity-97.01-SMILES-C[C@@H](C(N[C@H](C)[C@H](C1=CC=CC=C1)O)=O)[C@H]([C@@](CCC2)([H])N2C(C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C(OCC(C=C3)=CC=C3NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC(CON)=O)=O)=O)=O)=O)=O)=O)OC-Research_Area-Cancer-Solubility-DMSO : 100 mg/mL (ultrasonic)-Target-Drug-Linker Conjugates for ADC-Isoform–Pathway-Antibody-drug Conjugate/ADC Related-MCE Product type-ADC Related